The global public health landscape continues to evolve, and China’s rare disease sector is entering a phase of structural transformation. The 2026 China Rare Disease Industry Trend Observation Report provides a systematic analysis of policy frameworks, clinical systems, innovation capacity, and reimbursement mechanisms, outlining the industry’s transition from institutional establishment to coordinated system development.
The refinement of the national rare disease catalogues and the advancement of multi-layered support mechanisms are driving governance upgrades. Innovation capability is strengthening, domestic participation is expanding, and industry momentum is shifting from import reliance toward innovation leadership. The deepening of multidisciplinary clinical systems reinforces foundational capacity, placing operational quality at the center of development.
Treatment accessibility and reimbursement efficiency represent the defining variables of the current stage. As institutional maturity increases, coordination efficiency, innovation translation speed, and patient-level outcomes emerge as key determinants of long-term industry stability.
China’s rare disease sector is forming a more structured and integrated development framework, with high-quality growth increasingly established as the prevailing trajectory.
